NKARTA INC. - COMMON

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

10 Aug 2023 07:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conference

03 Aug 2023 08:02:00 By Nasdaq GlobeNewswire

Nkarta Appoints Alyssa Levin Chief Financial and Business Officer

05 Jul 2023 16:02:16 By Nasdaq GlobeNewswire

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

27 Jun 2023 07:01:00 By Nasdaq GlobeNewswire

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program

26 Jun 2023 16:01:00 By Nasdaq GlobeNewswire

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

10 Jun 2023 10:47:47 By Nasdaq GlobeNewswire

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

11 May 2023 16:02:00 By Nasdaq GlobeNewswire

Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

11 May 2023 16:01:01 By Nasdaq GlobeNewswire

Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting

17 Apr 2023 17:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conferences

12 Apr 2023 21:06:30 By Nasdaq GlobeNewswire

Nkarta Announces Departure of Chief Financial & Business Officer

30 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

16 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conferences

09 Feb 2023 08:02:00 By Nasdaq GlobeNewswire

Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer

09 Jan 2023 16:30:23 By Nasdaq GlobeNewswire

Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

05 Dec 2022 07:02:00 By Nasdaq GlobeNewswire

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program

02 Dec 2022 16:02:00 By Nasdaq GlobeNewswire

Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

09 Nov 2022 16:02:00 By Nasdaq GlobeNewswire

Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting

07 Nov 2022 08:52:47 By Nasdaq GlobeNewswire

Nkarta to Participate at Upcoming Investor Conferences

02 Nov 2022 08:02:00 By Nasdaq GlobeNewswire

Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights

11 Aug 2022 16:02:00 By Nasdaq GlobeNewswire